Sanjiv S Agarwala

Summary

Affiliation: St. Luke's Hospital
Country: USA

Publications

  1. doi request reprint Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach
    Sanjiv S Agarwala
    Medical Oncology and Hematology, St Luke s Cancer Center, 801 Ostrum Street, Bethlehem, PA 18015, USA
    Cancer Treat Rev 37:133-42. 2011
  2. doi request reprint An update on pegylated IFN-α2b for the adjuvant treatment of melanoma
    Sanjiv S Agarwala
    St Luke s Cancer Center, 801 Ostrum Street, Bethlehem, PA 18015, USA
    Expert Rev Anticancer Ther 12:1449-59. 2012
  3. pmc Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review
    Sanjiv S Agarwala
    Oncology and Hematology, St Luke s Cancer Center, 801 Ostrum Street, Bethlehem, Pennsylvania 18015, USA
    Oncologist 15:236-45. 2010
  4. doi request reprint Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma
    Sanjiv S Agarwala
    Medical Oncology and Hematology, St Luke s Cancer Center, Bethlehem, Pennsylvania 18015, USA
    Melanoma Res 20:1-10. 2010
  5. doi request reprint Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008
    Sanjiv S Agarwala
    Oncology and Hematology, St Luke s Cancer Center, Bethlehem, PA, USA
    Pigment Cell Melanoma Res 22:532-43. 2009
  6. doi request reprint Current systemic therapy for metastatic melanoma
    Sanjiv S Agarwala
    St Luke s Cancer Center, University of Pennsylvania, Bethlehem, PA, USA
    Expert Rev Anticancer Ther 9:587-95. 2009
  7. doi request reprint Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer 112:1131-8. 2008
  8. ncbi request reprint Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    J Clin Oncol 25:3802-7. 2007
  9. doi request reprint Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma
    Chi Chang Chen
    Health Economics and Outcomes Research, IMS Health, Plymouth Meeting, PA, USA
    Clin Genitourin Cancer 10:256-61. 2012
  10. doi request reprint LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
    Sanjiv S Agarwala
    St Luke s Cancer Center, Bethlehem, PA 18015, USA
    Eur J Cancer 45:1807-14. 2009

Detail Information

Publications14

  1. doi request reprint Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach
    Sanjiv S Agarwala
    Medical Oncology and Hematology, St Luke s Cancer Center, 801 Ostrum Street, Bethlehem, PA 18015, USA
    Cancer Treat Rev 37:133-42. 2011
    ..Here, we provide an overview of the current unmet needs in the adjuvant therapy of melanoma and evaluate the potential of CTLA-4 blockade as a future therapeutic option in this setting...
  2. doi request reprint An update on pegylated IFN-α2b for the adjuvant treatment of melanoma
    Sanjiv S Agarwala
    St Luke s Cancer Center, 801 Ostrum Street, Bethlehem, PA 18015, USA
    Expert Rev Anticancer Ther 12:1449-59. 2012
    ..In addition, emerging evidence suggests that PEG-IFN-α2b therapy may provide clinically significant overall survival benefit for selected high-risk patients...
  3. pmc Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review
    Sanjiv S Agarwala
    Oncology and Hematology, St Luke s Cancer Center, 801 Ostrum Street, Bethlehem, Pennsylvania 18015, USA
    Oncologist 15:236-45. 2010
    ..This review describes the clinical development of everolimus in advanced RCC and the rationale for the use of mTOR inhibitors after failure of VEGF/VEGFR inhibitors...
  4. doi request reprint Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma
    Sanjiv S Agarwala
    Medical Oncology and Hematology, St Luke s Cancer Center, Bethlehem, Pennsylvania 18015, USA
    Melanoma Res 20:1-10. 2010
    ..Novel combinations are reviewed in the context of creating an immunosupportive environment in the host...
  5. doi request reprint Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008
    Sanjiv S Agarwala
    Oncology and Hematology, St Luke s Cancer Center, Bethlehem, PA, USA
    Pigment Cell Melanoma Res 22:532-43. 2009
    ....
  6. doi request reprint Current systemic therapy for metastatic melanoma
    Sanjiv S Agarwala
    St Luke s Cancer Center, University of Pennsylvania, Bethlehem, PA, USA
    Expert Rev Anticancer Ther 9:587-95. 2009
    ..Research is ongoing in exploring novel immunotherapeutic and targeted approaches. The status of recently completed and ongoing trials is discussed in this review...
  7. doi request reprint Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer 112:1131-8. 2008
    ..Arsenic trioxide (ATO) cytotoxicity and apoptosis induction has been demonstrated with numerous cancer cell lines, including human melanoma...
  8. ncbi request reprint Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    J Clin Oncol 25:3802-7. 2007
    ..We conducted a phase II trial of high-dose bolus (HDB) interleukin-2 (IL-2) in patients with metastatic melanoma who had experienced progression after biochemotherapy (BCT)...
  9. doi request reprint Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma
    Chi Chang Chen
    Health Economics and Outcomes Research, IMS Health, Plymouth Meeting, PA, USA
    Clin Genitourin Cancer 10:256-61. 2012
    ..02-3.07]; P = .043). The results of this real-world data analysis suggest that the risk of second-line treatment failure after first-line sunitinib was significantly higher with temsirolimus and sorafenib compared with everolimus...
  10. doi request reprint LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
    Sanjiv S Agarwala
    St Luke s Cancer Center, Bethlehem, PA 18015, USA
    Eur J Cancer 45:1807-14. 2009
    ..1xupper limit of normal (ULN)]. Each stratification factor was assessed for an interaction with treatment on survival and an interaction was detected only for LDH...
  11. doi request reprint Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors
    Sanjiv S Agarwala
    Department of Oncology and Hematology, St Luke s Cancer Center, Bethlehem, Pennsylvania 18015, USA
    J Immunother 33:557-69. 2010
    ....
  12. ncbi request reprint Radiosurgery for the treatment of spinal melanoma metastases
    Peter C Gerszten
    Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Stereotact Funct Neurosurg 83:213-21. 2005
    ..This study evaluated the clinical efficacy of radiosurgery for the treatment of melanoma spinal metastases in 28 patients...
  13. doi request reprint Melanoma vaccines
    Lee B Riley
    St Luke s Cancer Center, St Luke s Hospital and Health Network, 801 Ostrum Street, Bethlehem, PA 18015, USA
    Expert Rev Vaccines 7:937-49. 2008
    ..The objective of this review is to provide an overall summary of recent clinical trials with melanoma vaccines and highlight novel vaccine strategies to evaluate in the near future...
  14. ncbi request reprint Novel agents in development for the treatment of melanoma
    Ahmad A Tarhini
    Division of Medical Oncology and Hematology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Expert Opin Investig Drugs 14:885-92. 2005
    ....